Drug Trial Radar · NCT05466877
A Study of MG-K10 in Subjects With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
163
Planned (sponsor's estimate)
Start
Aug 31, 2022
Primary completion
Sep 22, 2023
Study completion May 26, 2024
Sponsor
- Lead sponsor
- Shanghai Mabgeek Biotech.Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the preliminary efficacy of MG-K10 in subjects with moderate to severe asthma, and provides a basis for the design and dosing regimen of phase III clinical trials.
Conditions
- Atopic Dermatitis
Interventions
MG-K10Drug
MG-K10 Humanized Monoclonal Antibody Injection
PlaceboDrug
MG-K10 Humanized Monoclonal Antibody Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change from baseline in EASITime frame: 16 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China
Huashan Hospital Affiliated to Fudan University
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.